Literature DB >> 35369564

Screening and Recognition of Chronic Kidney Disease in VA Health Care System Primary Care Clinics.

Shweta Bansal1,2, Michael Mader2, Jacqueline A Pugh2,3.   

Abstract

Background: The successful implementation of interventions targeted to improve kidney health requires early identification of CKD which involves screening at-risk populations as well as recognizing CKD. We aim to determine CKD screening and recognition rates, factors associated with these rates, and evaluate the effect of CKD awareness on delivery of care.
Methods: A retrospective cohort study of veterans enrolled with Veterans Integrated Service Network 17 who had hypertension (HTN) and/or diabetes (DM) and were seen at least twice in primary care clinics within 18 months. The final cohort of 270,170 patients (52% HTN, 5% DM, and 44% both) was examined for serum creatinine/eGFR, urine protein/albumin, International Classification of Diseases (ICD) codes for CKD, and nephrology referral. CKD was defined as eGFR <60 ml/min per 1.73 m2 and/or urine albumin-creatinine ratio (uACR) >30 mg/g at least twice 90 days apart. Clinical covariates, HTN control, and prescription rates of renal prudent medications and nonsteroidal anti-inflammatory drugs (NSAIDs) were assessed.
Results: Overall, 254,831 (94%) patients had either eGFR, urine protein/albumin, or both. However, screening for protein/albuminuria was low (56%), particularly in patients with isolated HTN (35%). Of 254,831 patients, 92,900 (36%) had laboratory evidence of CKD and, of these, 40,586 (44%) were recognized to have CKD by ICD code and/or nephrology referral. CKD due to presence of uACR criteria alone had the lowest recognition (19%) as compared with CKD due to eGFR criteria (44%) or both (67%). Frequency of emergency room visits, hospitalization, and cardiac and endovascular procedures requiring contrast had the highest odds and races other than white had the lower odds of screening. In contrast, CKD recognition was high in races other than white and increased with worsening eGFR and increasing uACR. In screened and recognized CKD, prescription was higher for angiotensin inhibitors, statins, and diuretics, and was lower for NSAIDs. Conclusions: Although overall CKD screening rate was high, screening of protein/albuminuria in isolated HTN and overall recognition of CKD was low in at-risk veterans. Increased recognition was associated with a favorable prescription rate for renal prudent medications.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  International Classification of Diseases; albuminuria; awareness; chronic; chronic kidney disease; diuretics; glomerular filtration rate; hypertension; kidney function tests; proteinuria; renal insufficiency; retrospective studies; screening; urinalysis

Mesh:

Year:  2020        PMID: 35369564      PMCID: PMC8815593          DOI: 10.34067/KID.0000532020

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  18 in total

1.  Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.

Authors:  Anjali Tiwari; Chin-Lin Tseng; Elizabeth F O Kern; Miriam Maney; Donald R Miller; Leonard Pogach
Journal:  Am J Manag Care       Date:  2007-02       Impact factor: 2.229

Review 2.  Treatment of hypertension in chronic kidney disease.

Authors:  Robert D Toto
Journal:  Semin Nephrol       Date:  2005-11       Impact factor: 5.299

3.  Trends in Prevalence of Chronic Kidney Disease in the United States.

Authors:  Daniel Murphy; Charles E McCulloch; Feng Lin; Tanushree Banerjee; Jennifer L Bragg-Gresham; Mark S Eberhardt; Hal Morgenstern; Meda E Pavkov; Rajiv Saran; Neil R Powe; Chi-Yuan Hsu
Journal:  Ann Intern Med       Date:  2016-08-02       Impact factor: 25.391

Review 4.  Population Health for CKD and Diabetes: Lessons From the Indian Health Service.

Authors:  Andrew Narva
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 8.860

5.  Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.

Authors:  Joi Lee; Chi Chu; David Guzman; Valy Fontil; Alexandra Velasquez; Neil R Powe; Delphine S Tuot
Journal:  Am J Nephrol       Date:  2019-06-05       Impact factor: 3.754

6.  Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Paul Muntner; Amanda Anderson; Jeanne Charleston; Zhen Chen; Virginia Ford; Gail Makos; Andrew O'Connor; Kalyani Perumal; Mahboob Rahman; Susan Steigerwalt; Valerie Teal; Raymond Townsend; Matthew Weir; Jackson T Wright
Journal:  Am J Kidney Dis       Date:  2009-12-05       Impact factor: 8.860

7.  Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort study.

Authors:  Idris Guessous; William McClellan; Suma Vupputuri; Haimanot Wasse
Journal:  BMC Nephrol       Date:  2009-09-16       Impact factor: 2.388

8.  Recognition and management of chronic kidney disease in an elderly ambulatory population.

Authors:  Michael B Rothberg; Eileen D Kehoe; Abbie L Courtemanche; Thabo Kenosi; Penelope S Pekow; Maura J Brennan; Jeffrey G Mulhern; Gregory L Braden
Journal:  J Gen Intern Med       Date:  2008-04-29       Impact factor: 5.128

9.  Electronic problem list documentation of chronic kidney disease and quality of care.

Authors:  Lipika Samal; Jeffrey A Linder; David W Bates; Adam Wright
Journal:  BMC Nephrol       Date:  2014-05-04       Impact factor: 2.388

10.  Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care.

Authors:  Martin Frigaard; Anna Rubinsky; Lo Lowell; Anna Malkina; Leah Karliner; Michael Kohn; Carmen A Peralta
Journal:  BMC Nephrol       Date:  2019-01-03       Impact factor: 2.388

View more
  1 in total

Review 1.  Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials.

Authors:  Peter A McCullough; Alpesh Amin; Kevin M Pantalone; Claudio Ronco
Journal:  J Am Heart Assoc       Date:  2022-05-26       Impact factor: 6.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.